Phase 3 Study Comparing TAK-881 and HYQVIA Subcutaneous Treatments in Adults with Chronic Inflammatory Demyelinating Polyradiculoneuropathy CIDP

What this Trial Is About

Researchers are evaluating the pharmacokinetic comparability between TAK-881 and HYQVIA when given as subcutaneous injections for maintenance therapy in adults with chronic inflammatory demyelinating polyradiculoneuropathy CIDP. This phase 3 trial focuses on participants who have been receiving intravenous or subcutaneous immunoglobulin treatments and aims to compare these two treatments in terms of how the body absorbs and processes them. The study includes several phases starting with screening and possibly a ramp-up phase for those switching treatments. Participants already on HYQVIA go directly to that treatment phase, which lasts 18 to 20 weeks depending on dosing intervals. Then all participants switch to TAK-881 for 24 weeks. After this, an extension phase allows continued treatment for up to 3 years, with home infusions permitted and clinic visits spaced between 12 and 24 weeks. Treatments are given by subcutaneous infusion using specialized needle sets. Participants will visit the clinic every 3 or 4 weeks during the initial phases to undergo assessments including blood sampling to measure immunoglobulin G levels at various time points. The study also tracks clinical disability scores, hand grip strength, muscle strength, and adverse events over time. Safety and treatment tolerability are closely monitored throughout the trial. Total participation may last several years including the extension phase.

A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)